The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global drug screening market was valued at US$ 5.42 Billion in 2021.
We expect the global drug screening market to exhibit a CAGR of 9.30% during 2022-2027.
The growing utilization of drug screening procedures in clinical care, occupational health, legal prosecution, and professional sports to detect the presence of the drug in the body is primarily driving the global drug screening market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of drug screening procedures to reduce the risk of the coronavirus infection upon hospital visits or interaction with healthcare professionals, thereby negatively impacting the demand for drug screenings.
Based on the product and service, the global drug screening market can be categorized into equipment, rapid testing devices, consumables, and laboratory services. Currently, rapid testing devices exhibit clear dominance in the market.
Based on the sample type, the global drug screening market has been segmented into urine samples, breath samples, oral fluid samples, hair samples, and others. Among these, urine samples currently represent the largest market share.
Based on the end user, the global drug screening market can be bifurcated into hospitals, drug testing laboratories, workplaces, drug treatment centers, pain management centers, personal users, and criminal justice system and law enforcement agencies. Currently, workplaces account for the majority of the total market share.
On a regional level, the market has been classified into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global drug screening market include Abbott Laboratories, Alfa Scientific Designs Inc., Bio-Rad Laboratories Inc., Drägerwerk AG & Co. KGaA, Laboratory Corporation of America Holdings, Lifeloc Technologies Inc., Omega Laboratories Inc., OraSure Technologies Inc., Psychemedics Corporation, Quest Diagnostics Incorporated, Siemens AG, and Thermo Fisher Scientific Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at